Cancer

human T cells in culture

Politics

Medicare would provide national coverage for CAR-T cancer therapies under new proposal

By Ike Swetlitz

China lung cancer scan

Pharmalot

Drug company payments for consulting and speaking influence oncologists’ prescribing

By Ed Silverman

advertisement

Something ventured illo

Biotech

Something Ventured: Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

advertisement

John V. Oyler, CEO of BeiGene

Biotech

For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By Rebecca Robbins

Macrophage - glioblastoma

Health

An early study ‘infuses hope’ back into attempts to use immunotherapy to treat brain cancer

By Andrew Joseph

Sean Parker

Heavyweights

Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials

Grace Eline

In the Lab

Trump’s $500 million for childhood cancer? Scientists have ideas how to spend it

By Sharon Begley

advertisement

Breast Cancer Cell

Biotech

New York biotech debuts, targeting dormant metastatic cancer cells

By Sharon Begley

advertisement

Pharmalot

Pharmalittle: Trump leaves Democrats confused over drug pricing; Vertex dismisses U.K. licensing threat

By Ed Silverman

Infusion at home

First Opinion

Cancer treatment at home is safe, effective, and closer to happening than you think

By Nathan R. Handley and Justin E. Bekelman

Dana Farber Cancer Institute.

In the Lab

Dana-Farber heads to court to add researcher on immunotherapy patents

By Elizabeth Cooney

Fake cures - cancer

Health

The modern tragedy of fake cancer cures

By Matthew Herper

Broken pill

First Opinion

The downside of inflammatory news about cancer

By Dena Battle

Herceptin

Pharmalot

Swiss government is asked to issue a compulsory license for a Roche cancer drug

By Ed Silverman

Genetic Frontiers Living Cancer Drugs

Biotech

These pricey new cancer therapies are custom-made. Can they ever be more mainstream?

By Ike Swetlitz

Asuncion, Paraguay

First Opinion

Combating cancer around the world means keeping patients at the center

By Julie L. Gerberding

Using VR to see cancer

Health

Watch: He wanted to see his cancer from the inside. With virtual reality, he can

By Dominic Smith

Bristol-Myers Squibb

Biotech

In disappointment, Bristol pulls FDA application for Opdivo combination in lung cancer

By Matthew Herper

Pharmalot

The World Health Organization says cancer drug prices are ‘impairing’ access to treatment

By Ed Silverman

Toby the dog

Business

With human drugs, a Silicon Valley startup hopes to deliver precision medicine to dogs

By Rebecca Robbins

Video

Watch: To detect cancer, these researchers are turning to an unlikely source

By Hyacinth Empinado

Special Report

Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing

By Matthew Herper

Pancreatic Cancer Cells

Biotech

Tyme Technologies misleads with new data on pancreatic cancer drug

By Matthew Herper

FDA

Biotech

FDA rejects Immunomedics breast cancer drug, extending long regulatory drought

By Adam Feuerstein

Digital pill illustration part deux

Health

A ‘digital pill’ for cancer patients is rolled out for the first time, in hopes of improving outcomes

By Rebecca Robbins

Diversity in clinical trials concept

First Opinion

Diversity in clinical trials defines good science and better medicine

By Jane L. Delgado and Edward Abrahams

Triple-negative breast cancer

Biotech

After 37 years of trying, this biotech nears a first drug approval in breast cancer

By Adam Feuerstein

IV Drip

In the Lab

New study points to best way to assess which cancer patients immunotherapy will help

By Sharon Begley

Ginni Rometty CES

Exclusive

IBM isn’t retreating from using Watson in health care, CEO Rometty says